Material Data Sheet

Human SUMO1, MAb

Price: $229.00
Catalog #: A-722

Human SUMO1, MAb

50 µg
Data Sheet: 

Small Ubiquitin-like Modifiers (SUMOs) are a family of proteins that can be enzymatically attached to a target protein by a post-translational modification process termed SUMOylation. Unlike ubiquitination, which targets proteins for degradation, SUMOylation participates in a number of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. All human SUMO proteins share a conserved Ubiquitin-like domain and a C-terminal diglycine cleavage/attachment site. Human SUMO1, also known as Sentrin, UBL1, and SMT3C, is synthesized as a 101 amino acid (aa) propeptide that contains a four aa C-terminal prosegment. Following prosegment cleavage, the C-terminal glycine may be enzymatically attached to a lysine on a target protein. Human SUMO1 shares 100% sequence identity to SUMO1 from mouse. SUMO1 is the most unique of the four identified SUMO proteins and shares only 44%, 47%, and 41% sequence identity to SUMO2, SUMO3, and SUMO4, respectively.

Product Information

0.5 mg/mL in PBS, pH 7.4, 50% (v/v) Glycerol, 0.09% sodium azide

Use & Storage


Recommended concentration for Western Blot is 0.1 - 0.5 μg/ml. Recommended IP conditions: use 10-20 μg of A-722 to recover SUMOylated proteins from 0.5 – 1 mg of total protein in 1 ml of cellular lysate. Use of Sentrin Protease inhibitors such as SUMO1-Vinyl Sulfone may increase yields of recovered SUMOylated substrates.


Store at -20°C

This antibody detects endogenous, human SUMOylated proteins in Western blots. Cross-reactive against murine and rat proteins.